The IMID Forum
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
All episodes(52)
- StandardSummaries onlyDiscussing PsA: Personalising treatment targets – understanding clinically meaningful improvement
Published Jun 18, 2026
Join Professor Laura Coates and Professor Philip Mease as they discuss a recent publication examining minimal clinically important improvement thresholds in psoriatic arthritis. This month’s conversation explores how patients with differing levels of baseline disease activity may require different degrees of improvement before perceiving treatment benefit, highlighting the potential for more personalised treatment targets and shared decision making in PsA.
- StandardSummaries onlyEULAR 2026 Review Podcast
Published Jun 12, 2026
Join Professors Xenofon Baraliakos, Laura Coates and Dr Sofia Ramiro as they break down the top RA, PsA and axSpA abstracts, sessions and posters from this year's EULAR conference.
- StandardSummaries onlyEULAR 2026 Day 4 Highlights Podcast
Published Jun 6, 2026
Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 4 of EULAR 2026 (Saturday, June 6th).
- StandardSummaries onlyEULAR 2026 Day 3 Highlights Podcast
Published Jun 5, 2026
Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 3 of EULAR 2026 (Friday, June 5th).
- StandardSummaries onlyEULAR 2026 Day 2 Highlights Podcast
Published Jun 4, 2026
Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 2 of EULAR 2026 (Thursday, June 4th).
- StandardSummaries onlyEULAR 2025 Day 1 Highlights Podcast
Published Jun 3, 2026
Join Professor Sofia Ramiro as she summarises her top RA, PsA and axSpA abstracts, posters, and presentations for Day 1 of EULAR 2026 (Wednesday, June 3rd).
- StandardSummaries onlyDiscussing RA: Comparative outcomes with upadacitinib in RA
Published May 28, 2026
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review papers by Mysler et al. and Taylor et al, in which authors explore how different treatment strategies may improve outcomes in patients with RA.
- StandardSummaries onlyEULAR 2026 Preview Podcast
Published May 27, 2026
Join Professor Xenofon Baraliakos as he guides you through what we are most looking forward to in RA, PsA, and axSpA at EULAR 2026, so that you can better plan your time at what will be a busy and exciting congress
- StandardSummaries onlyDiscussing axSpA: Biologic therapy outcomes in axial spondyloarthritis
Published May 15, 2026
Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.
- StandardSummaries onlyAuthor Interview: Professor Valentino Paci, April 2026
Published Apr 30, 2026
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and am Professor Valentino Paci, Medical researcher specialized in immune-mediated diseases, with a particular focus on spondyloarthritis. Collaboration and knowledge exchange are integral to his research philosophy, as they discuss his recent paper ‘Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis?’.
- StandardSummaries onlyDiscussing RA: Updated EULAR recommendations and next-step strategies after TNF inhibitor failure
Published Apr 30, 2026
Join Professor Iain McInnes and Professor Rieke Alten for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they will review a paper by Smolen et al. provides an update of the EULAR RA management recommendations addressing the most recent insights; and by Narváez et al. developed evidence-informed, profile-based recommendations to guide treatment selection after inadequate response to a first TNFi in RA, combining evidence and expert consensu
- StandardSummaries onlyDiscussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile
Published Apr 14, 2026
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘safety and clinical efficacy of bimekizumab in patients with active PsA who were bDMARD-naïve or TNFi-IR, and the second provided a comprehensive and updated overview of bimekizumab’s safety profile to support clinical decision-making.
- StandardSummaries onlyAuthor Interview: Professor Helena Marzo-Ortega, March 2026
Published Apr 9, 2026
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and Professor Helena Marzo-Ortega an academic clinician and the Clinical Lead of the multi-award winning Leeds Specialist Spondyloarthropathy service at The Leeds Teaching Hospitals NHS Trust, as they discuss her recent paper ‘EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis’.
- StandardSummaries onlyDiscussing RA: Malignancy risk in patients with RA and the evolution of JAKi prescriptions
Published Mar 26, 2026
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper a paper on the malignancy risk in patients with RA initiating b/tsDMARDS, and the evolution of JAKi prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers.
- StandardSummaries onlyDiscussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers
Published Mar 19, 2026
Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.
- StandardSummaries onlyAuthor Interview: Doctor Carlo Tur, February 2026
Published Mar 12, 2026
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and Doctor Carlo Tur, from the department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University, Erlangen-Nurnberg., as they discuss his recent paper ‘Effects of different B-cell-depleting strategies on the lymphatic tissue’.
- StandardSummaries onlyAuthor Interview - Professor Andrew Cope, 2026
Published Mar 5, 2026
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from the Centre for Rheumatic Diseases, King’s College London, London, UK, as they discuss his recent paper ‘Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial’.
- StandardSummaries onlyDiscussing RA: Pain outcomes and drug effectiveness of JAK inhibitors in RA and PsA
Published Feb 27, 2026
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Taylor et al. where authors report the effects of UPA and ADA on pain in patients with active RA or PsA stratified by inflammatory status, and a paper by Sonomoto et al. which shows the effectiveness of TOF, BAR, UPA and FIL in patients with RA.
- StandardSummaries onlyDiscussing PsA: Risankizumab efficacy across machine learning defined and complex PsA phenotypes
Published Feb 13, 2026
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘classification of patients into distinct PsA phenotypes based on baseline demographics and clinical characteristics using a machine learning approach, and consensus-derived GRAPPA terminology, to support shared clinical decision making, and enable more effective patient stratification in both observational studies and clinical trials.
- StandardSummaries onlyAuthor Interview: Professor Matthew Brown, 2026
Published Feb 3, 2026
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and Professor Matthew Brown, the Chief Scientific Officer at Genomics England, as they discuss his recent paper ‘Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials’.
- StandardSummaries onlyDiscussing RA: Long-term effectiveness and sex differences of JAK inhibitors in rheumatoid arthritis
Published Jan 29, 2026
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Strand et al. that evaluated TOF efficacy, safety, and persistence by sex, and explored whether age-related factors contribute to differences in treatment response between males and females, and by Alten et al. that explored the long‑term effectiveness of baricitinib and other b/tsDMARDs in patients with RA with early low disease activi
- StandardSummaries onlyDiscussing RA: UPA outcomes and the impact of GCs on targeted therapies in RA
Published Dec 18, 2025
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he and Doctor Reike Alten will be reviewing two papers. The first paper by Kameda et al. assessed long-term safety and efficacy of UPA over 5 years in Japanese patients with moderate-to- severe active RA and an inadequate response to stable doses of csDMARDs-IR. The second paper by Salvato et al. assessed the impact of chronic oral low-dose GCs on the efficacy a
- StandardSummaries onlyDiscussing axSpA: Real-world outcomes for patients with axSpA receiving SC infliximab
Published Dec 11, 2025
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered a retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab
- StandardSummaries onlyDiscussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA
Published Dec 4, 2025
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.
- StandardSummaries onlyDiscussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA
Published Nov 27, 2025
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors
- StandardSummaries onlyAuthor Interview: Professor Filip Rob, 2025
Published Nov 20, 2025
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients’.
- StandardSummaries onlyWebinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2
Published Nov 16, 2025
Webinar HighlightsWebinar highlights! Join Professor Iain McInnes and Drs Grace Wright and Melinda Gooderham as they discuss advancing patient care through an interdisciplinary approach to IMIDs. This webinar provides information on bridging care pathways, advancing IMID treatment, and case studies of interdisciplinary care.
- StandardSummaries onlyDiscussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis
Published Nov 13, 2025
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
- StandardSummaries onlyDiscussing RA: Long-term management of elderly patients with RA treated with tocilizumab
Published Nov 6, 2025
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, Iain will review a paper by B Fautrel, in which authors compare patient characteristics and long-term management with tocilizumab in RA patients over and under 75 years of age, and tolerance of RA treatments.
- StandardSummaries onlyACR 2025 Review Podcast
Published Nov 5, 2025
Join Doctor Sofia Ramiro and Professors Janet Pope and Atul Deodhar, as they review and discuss key data from ACR 2025 across RA, PsA, and axSpA, focusing on implications for clinical practice.
- StandardSummaries onlyACR Daily Highlights Day 4
Published Oct 29, 2025
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 4 of ACR 2025 (Wednesdsy, 29th of October)
- StandardSummaries onlyACR Daily Highlights: Day 3
Published Oct 28, 2025
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of ACR 2025 (Tuesday 28th of October)
- StandardSummaries onlyPathways Modulating IMIDs: Webinar Highlights Podcast
Published Oct 28, 2025
Professors Janet Pope and John Isaacs discuss all the highlights from the 'Pathways Modulating IMIDs' webinar.
- StandardSummaries onlyACR Daily Highlights: Day 2
Published Oct 27, 2025
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of ACR 2025 (Monday, 27th of October)
- StandardSummaries onlyACR Daily Highlights: Day 1
Published Oct 26, 2025
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of ACR 2025 (Sunday, 26th of October)
- StandardSummaries onlyACR 2025 Preview Podcast
Published Oct 22, 2025
Join Professors Peter Nash, Janet Pope and Atul Deodhar as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2025
- StandardSummaries onlyDiscussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies
Published Oct 9, 2025
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.
- StandardSummaries onlyAuthor Interview: Doctor David Kellner, September 2025
Published Oct 2, 2025
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology, from UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.
- StandardSummaries onlyDiscussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases
Published Sep 25, 2025
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.
- StandardSummaries onlyDiscussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA
Published Sep 18, 2025
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.
- StandardSummaries onlyDiscussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis
Published Sep 4, 2025
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month’s discussion covered the ‘Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis’. Read the full paper summary online at www.imidforum.com.
- StandardSummaries onlyAuthor Interview: Doctor Rodrigo Garcia‑Salinas, August 2025
Published Aug 28, 2025
Author InterviewJoin Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.
- StandardSummaries onlyAuthor Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025
Published Aug 14, 2025
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigating the comparative risk of malignancies in rheumatoid arthritis patients treated with JAK inhibitors versus bDMARDs.
- StandardSummaries onlyDiscussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials
Published Aug 7, 2025
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the influence of csDMARDs use on efficacy and safety of deucravacitinib in pateints with PsA’ and ‘the incidence rate of uveitis in patients with axSpA and PsA treated with secukinumab’.
- StandardSummaries onlyDiscussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting
Published Jul 31, 2025
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month, the conversation covered the ‘dual JAK and ROCK inhibition with CPL’116 in patients with RA with inadequate response to MTX’ and ‘the benefit–risk analysis of UPA versus adalimumab in patients with RA and higher or lower risk of cardiovascular disease’
- StandardSummaries onlyDiscussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA
Published Jul 10, 2025
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered treatment outcomes in European real-world patients with axSpA and PsA, treated with secukinumab and the effects of secukinumab on skeletal microarchitecture and vertebral fractures in patients with axSpA.
- StandardSummaries onlyDifficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash
Published Jul 3, 2025
Join Professor Iain McInnes from the University of Glasgow, and Professor Peter Nash from the Griffith University in Brisbane, as they discuss the concept of difficult-to-treat disease in rheumatology.
- StandardSummaries onlyEULAR 2025 Review Podcast
Published Jul 2, 2025
Join Professors Xenofon Baraliakos, Laura Coates, and Johannes Bijlsma as they review their highlights of the recent EULAR 2025 congress, and watch them discuss the key abstracts and information.
- StandardSummaries onlyDiscussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment
Published Jun 26, 2025
Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss three papers: the impact of TOF treatment on weight and BMI in RA patients, to that of alternate treatment options for RA patients with prior MTX-inadequate response, and the treatment of JAKis versus TNFis in RA.
- StandardSummaries onlyEULAR 2025 Highlights: Day 4
Published Jun 14, 2025
Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 4 of EULAR 2025 (Saturday, June 14).
- StandardSummaries onlyEULAR 2025 Highlights: Day 3
Published Jun 13, 2025
Join Professor Xenofon Baraliakos as he summarises his top abstracts, posters, and presentations from Day 3 of EULAR 2025 (Friday, June 13).
- StandardSummaries onlyDiscussing PsA: Real-world data on biologic switching and the development of EMMs
Published Jun 12, 2025
Join Professors Philip Mease and Laura Coates and as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on biologic switching for the treatment of PsA using real-world data as well as the development of extramusculoskeletal manifestations in PsA and axSpA patients treated with upadacitinib.